BioCentury
ARTICLE | Company News

Neos Therapeutics sales and marketing update

May 23, 2016 7:00 AM UTC

Neos launched once-daily Adzenys XR-ODT amphetamine in the U.S. to treat ADHD in patients ages six and older. The wholesale acquisition cost (WAC) of a 3.1, 6.3, 9.4, 12.5, 15.7 or 18.8 mg tablet is $9. The starting dose for pediatric patients is 6.3 mg, and the recommended adult dose is 12.5 mg. Adzenys XR-ODT is an extended-release, orally disintegrating tablet of amphetamine polistirex that uses Neos’ Rapidly Disintegrating Ionic Masking (RDIM) technology. ...